Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07830433) titled 'Evaluation of the Efficacy of Zuberitamab Injection in Patients With Primary Membranous Nephropathy' on Sept. 15.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: BioRay Pharmaceutical Co., Ltd.

Condition: Primary Membranous Nephropathy

Intervention: Drug: Zuberitamab 1000mg

Recruitment Status: Not recruiting

Phase: Phase 3

Date of First Enrollment: October 2026

Target Sample Size: 150

Countries of Recruitment: China

To know more, visit https://clinicaltrials.gov/study/NCT...